Future studies aiming to more robustly demonstrate improvements in overall glycemia by SSTR2a administration could be designed with more comprehensive recording of baseline glycemic parameters and evaluate changes without antecedent hypoglycemia and under different glycemic management strategies such as varying intensity of maintenance insulin dosing. This evidence concerns the gene INS and Hypoglycemia.